$0.44
1.88% yesterday
Nasdaq, Nov 15, 09:47 pm CET
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Altamira Therapeutics Ltd Stock price

$0.46
-0.13 22.83% 1M
-1.07 70.24% 6M
-3.02 86.91% YTD
-1.52 77.00% 1Y
-959.54 99.95% 3Y
-539.54 99.92% 5Y
-33,999.54 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.03 5.91%
ISIN
BMG0360L1000
Symbol
CYTO
Sector
Industry

Key metrics

Market capitalization $1.62m
Enterprise Value $1.98m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 0.18
Short interest 0.83%

Is Altamira Therapeutics Ltd a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Altamira Therapeutics Ltd Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Altamira Therapeutics Ltd:

Buy
100%

Financial data from Altamira Therapeutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
92% 92%
-
-0.13 -0.13
91% 91%
-
- Selling and Administrative Expenses 3.22 3.22
146% 146%
-
- Research and Development Expense 3.38 3.38
84% 84%
-
-6.73 -6.73
55% 55%
-
- Depreciation and Amortization 0.13 0.13
38% 38%
-
EBIT (Operating Income) EBIT -6.87 -6.87
55% 55%
-
Net Profit -4.31 -4.31
84% 84%
-

In millions USD.

Don't miss a Thing! We will send you all news about Altamira Therapeutics Ltd directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altamira Therapeutics Ltd Stock News

Neutral
GlobeNewsWire
about one month ago
Hamilton, Bermuda, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that it received on September 30, 2024, a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that it no longer complied with Rule 5550(a)(2) of Nasdaq's Listing Rules, which requires listed securities to maintain a m...
Neutral
GlobeNewsWire
about 2 months ago
Hamilton, Bermuda, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. obtained extended ISO 13485 certification for its quality management system, including henceforth also production activities. With this extension, the quality management system has been certified for the whol...
Neutral
Seeking Alpha
about 2 months ago
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q2 2024 Results Conference Call September 24, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Paneda - Chief Operating Officer Conference Call Participants Hunter Diamond - Diamond Equity Operator Good morning, and welcome to the Altamira Therapeutics First Half 2024 and Business Update Conferenc...
More Altamira Therapeutics Ltd News

Company Profile

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Head office Bermuda
CEO Thomas Meyer
Employees 12
Founded 2003
Website www.altamiratherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today